These findings support the notion that alterations in DNMT expression might contribute to the development and progression of high-grade ovarian carcinomas, i.e., through the establishment of a CpG island methylator phenotype in ovarian cancer. This evidence concerns the gene DNMT1 and ovarian cancer.